Abstract: M41L, L74I, K65R, M184V, and M184I related to NRTI, K103N to NNRTI, and N83D, M46I, I84V, V82A, L24I, L90M, I54V to the PI sites were identified using NGS.
Prevalence of transmitted drug resistance among ART-naive HIV-infected individuals, Beijing, 2015-2018.
PMID: 35092830
2022
Journal of global antimicrobial resistance
Abstract: The thymidine analogue mutations (TAMs) M41L/LM (4, 0.12%) and non-TAMs mutations M184V/MV/MI (8; 0.24%) were the primary NRTI-associated resistance mutations.
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
PMID: 35040990
2022
The Journal of antimicrobial chemotherapy
Abstract: In PLWH carrying an M184V/I substitution, OT RNA <50 copies/mL was 89.5% at M6.
Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa.
Abstract: K103N (59%) and M184V (52%) were the most common mutations, followed by V106M and K65R (31% each).
Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
PMID: 35001501
2022
Journal of the International AIDS Society
Abstract: Six (5.9%) participants experienced virologic failure, two of whom had RPV-associated mutations (K101E and Y181C) and a lamivudine-associated mutation (M184V/I).
Discussion: While no emergence of RPV resistance was observed in the 4.1% of study participants with virologic failure in the adult study, two of six adolescents with virologic failure in our study developed RPV RAMs (K101E and Y181C) and a lamivudine-associated mutation (M184V/I).
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
PMID: 34897227
2022
Journal of acquired immune deficiency syndromes (1999)
Result: Notably, 4 had INSTI-R combined with NRTI-R substitutions relevant to the emtricitabine (FTC) or TAF components of the B/F/TAF regimen (M184V and/or K70E).
Table: M184V/I
Table: M184V
Discussion: In the 3 real-world cases, other INSTI-R substitutions were also noted, including L74I, E138K, S147G, and H51Y, along with M184V in RT.
Discussion: The accumulation of multiple INSTI-R mutations, along with M184V, which confe
Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.
Abstract: M184V mutation was harboured more commonly in the recent PrEP use group (30% vs.
Abstract: DISCUSSION: Rapid PrEP intensification to ART allowed to achieve high rates of HIV viral suppression despite significant rates of M184V mutation harboured in those newly diagnosed with HIV and reporting recent PrEP exposure.
Result: Among those harbouring a Discussion: At least two-thirds of those carrying a M184V/I mutation in our cohort acquired HIV recently, with a large majority reporting sub-optimal PrEP adherence, irrespectively of the PrEP scheme adopted, confirming the trend observed previously in our cohort and in other reports.
Discussion: We confirm high rates of acquired viral resistance to emtricitabine, mostly in the form of M184V/I mutation, harboured in almost a third of these cases.
Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
PMID: 34871089
2022
Antimicrobial agents and chemotherapy
Result: The most frequent treatment-emergent NRTI RAM was M184V (4/15 patients [26.7%]).
Result: Three patients had both treatment-emergent RPV RAM E138K and NRTI RAM M184V at the last post-baseline time point with genotypic data.
Discussion: The most common treatment-emergent RPV and NRTI RAMs were E138K and M184V, respectively.
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study.
PMID: 34849981
2022
The Journal of antimicrobial chemotherapy
Abstract: CONCLUSIONS: Lamivudine/dolutegravir maintenance DT showed similar efficacy to dolutegravir-based TT; however, past M184V/I may favour VF.
Abstract: Conversely, in the setting of pre-existing M184V/I, DT showed a trend to increased risk of VF (versus tenofovir-based TT, aHR = 137.50, 95% CI = 4.24-4464.06; versus abacavir-based TT, aHR = 33.88, 95% CI = 1.75-656.47).
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
PMID: 34694877
2022
Antimicrobial agents and chemotherapy
Result: One participant (participant 1) had the integrase substitution R263R/K and NRTI resistance-associated substitutions K65R and M184I/V at baseline, despite no apparent prior INSTI treatment, but did not demonstrate in vitro dolutegravir phenotypic resistance.
Result: The
Discussion: Six participants received zidovudine as the active background agent, and all had M184V resistance substitutions with prior lamivudine or emtricitabine treatment.
Discussion: Unusually, 1 participant had the highly conserved integrase substitutions R263R/K and M184I/V as mixtures at baseline but not at CVW.
HIV mutation literature information.
PMID: 
2022
Current HIV research
Browser Board
Co-occurred Entities
Filtrator
ViMRT